Olaparib is a potent PARP inhibitor with IC50 of 5 and 1 nM for PARP1 and PARP2, respectively.

Veliparib is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM, respectively.

BMN-673 is a PARP1/2 inhibitor with IC50 of 0.57 nM for PARP1.

AG14361 is a potent inhibitor of PARP1 with Ki of < 5 nM.

A-966492 is a potent inhibitor of PARP1 and PARP2 with Ki of 1 nM and 1.5 nM, respectively.

MK-4827 is an excellent PARP1 and PARP2 inhibitor with IC50 of 3.8 and 2.1 nM, respectively.

UPF 1069 is a selective PARP2 inhibitor with IC50 of 0.3 μM, which is ~27-fold selective against PARP1.

ME0328 is a potent and selective PARP inhibitor with IC50 of 0.89 μM for PARP3, about 7-fold selectivity over PARP1.

E7449 is an orally bioavailable, potent, small molecule inhibitor of PARP1 and PARP2 and enhances the efficacy of radiotherapy and chemotherapy and has potent single agent anticancer activity in BRCA-deficient tumors.

MK-4827 tosylate is a selective inhibitor of PARP1/PARP2 with IC50 of 3.8 nM/2.1 nM and with great activity in cancer cells with mutant BRCA-1 and BRCA-2 and > 330-fold selective against PARP3, V-PARP and Tank1.

BSI-201 is a PARP1 inhibitor with demonstrated effectiveness in triple-negative breast cancer (TNBC).

NMS-P118 is a potent, orally available, and highly selective PARP-1 inhibitor for cancer therapy with an IC50 of 0.04 μM in HeLa cell.